328 related articles for article (PubMed ID: 24565907)
21. The heparanase/heparan sulfate proteoglycan axis: A potential new therapeutic target in sarcomas.
Cassinelli G; Zaffaroni N; Lanzi C
Cancer Lett; 2016 Nov; 382(2):245-254. PubMed ID: 27666777
[TBL] [Abstract][Full Text] [Related]
22. Heparanase multiple effects in cancer.
Nadir Y; Brenner B
Thromb Res; 2014 May; 133 Suppl 2():S90-4. PubMed ID: 24862152
[TBL] [Abstract][Full Text] [Related]
23. Heparanase: A Potential Therapeutic Target in Sarcomas.
Cassinelli G; Lanzi C
Adv Exp Med Biol; 2020; 1221():405-431. PubMed ID: 32274719
[TBL] [Abstract][Full Text] [Related]
24. Heparanase procoagulant effects and inhibition by heparins.
Nadir Y; Brenner B
Thromb Res; 2010 Apr; 125 Suppl 2():S72-6. PubMed ID: 20434010
[TBL] [Abstract][Full Text] [Related]
25. Heparan sulfate and heparanase as modulators of breast cancer progression.
Gomes AM; Stelling MP; Pavão MS
Biomed Res Int; 2013; 2013():852093. PubMed ID: 23984412
[TBL] [Abstract][Full Text] [Related]
26. Heparanase, heparin and the coagulation system in cancer progression.
Vlodavsky I; Ilan N; Nadir Y; Brenner B; Katz BZ; Naggi A; Torri G; Casu B; Sasisekharan R
Thromb Res; 2007; 120 Suppl 2():S112-20. PubMed ID: 18023704
[TBL] [Abstract][Full Text] [Related]
27. The Heparanase Regulatory Network in Health and Disease.
Mayfosh AJ; Nguyen TK; Hulett MD
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681753
[TBL] [Abstract][Full Text] [Related]
28. Assessment of Heparanase-Mediated Angiogenesis Using Microvascular Endothelial Cells: Identification of λ-Carrageenan Derivative as a Potent Anti Angiogenic Agent.
Poupard N; Badarou P; Fasani F; Groult H; Bridiau N; Sannier F; Bordenave-Juchereau S; Kieda C; Piot JM; Grillon C; Fruitier-Arnaudin I; Maugard T
Mar Drugs; 2017 May; 15(5):. PubMed ID: 28486399
[TBL] [Abstract][Full Text] [Related]
29. Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis.
Edovitsky E; Elkin M; Zcharia E; Peretz T; Vlodavsky I
J Natl Cancer Inst; 2004 Aug; 96(16):1219-30. PubMed ID: 15316057
[TBL] [Abstract][Full Text] [Related]
30. Heparanase-neutralizing antibodies attenuate lymphoma tumor growth and metastasis.
Weissmann M; Arvatz G; Horowitz N; Feld S; Naroditsky I; Zhang Y; Ng M; Hammond E; Nevo E; Vlodavsky I; Ilan N
Proc Natl Acad Sci U S A; 2016 Jan; 113(3):704-9. PubMed ID: 26729870
[TBL] [Abstract][Full Text] [Related]
31. Identification of Novel Class of Triazolo-Thiadiazoles as Potent Inhibitors of Human Heparanase and their Anticancer Activity.
Baburajeev CP; Mohan CD; Rangappa S; Mason DJ; Fuchs JE; Bender A; Barash U; Vlodavsky I; Basappa ; Rangappa KS
BMC Cancer; 2017 Mar; 17(1):235. PubMed ID: 28359266
[TBL] [Abstract][Full Text] [Related]
32. The impact of heparanese and heparin on cancer metastasis and angiogenesis.
Vlodavsky I; Abboud-Jarrous G; Elkin M; Naggi A; Casu B; Sasisekharan R; Ilan N
Pathophysiol Haemost Thromb; 2006; 35(1-2):116-27. PubMed ID: 16855356
[TBL] [Abstract][Full Text] [Related]
33. PG545, a heparan sulfate mimetic, reduces heparanase expression in vivo, blocks spontaneous metastases and enhances overall survival in the 4T1 breast carcinoma model.
Hammond E; Brandt R; Dredge K
PLoS One; 2012; 7(12):e52175. PubMed ID: 23300607
[TBL] [Abstract][Full Text] [Related]
34. The heparanase system and tumor metastasis: is heparanase the seed and soil?
Arvatz G; Shafat I; Levy-Adam F; Ilan N; Vlodavsky I
Cancer Metastasis Rev; 2011 Jun; 30(2):253-68. PubMed ID: 21308479
[TBL] [Abstract][Full Text] [Related]
35. Heparanase: one molecule with multiple functions in cancer progression.
Vlodavsky I; Elkin M; Abboud-Jarrous G; Levi-Adam F; Fuks L; Shafat I; Ilan N
Connect Tissue Res; 2008; 49(3):207-10. PubMed ID: 18661344
[TBL] [Abstract][Full Text] [Related]
36. Heparanase regulation of cancer, autophagy and inflammation: new mechanisms and targets for therapy.
Sanderson RD; Elkin M; Rapraeger AC; Ilan N; Vlodavsky I
FEBS J; 2017 Jan; 284(1):42-55. PubMed ID: 27758044
[TBL] [Abstract][Full Text] [Related]
37. Heparanase enzyme in chronic inflammatory bowel disease and colon cancer.
Hermano E; Lerner I; Elkin M
Cell Mol Life Sci; 2012 Aug; 69(15):2501-13. PubMed ID: 22331282
[TBL] [Abstract][Full Text] [Related]
38. Heparanase procoagulant activity in cancer progression.
Nadir Y; Brenner B
Thromb Res; 2016 Apr; 140 Suppl 1():S44-8. PubMed ID: 27067977
[TBL] [Abstract][Full Text] [Related]
39. Heparanase as a molecular target of cancer chemotherapy.
Simizu S; Ishida K; Osada H
Cancer Sci; 2004 Jul; 95(7):553-8. PubMed ID: 15245589
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of heparanase activity and heparanase-induced angiogenesis by suramin analogues.
Marchetti D; Reiland J; Erwin B; Roy M
Int J Cancer; 2003 Mar; 104(2):167-74. PubMed ID: 12569571
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
